United States Food and Drug Administration
"United States Food and Drug Administration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
| Descriptor ID |
D014486
|
| MeSH Number(s) |
I01.409.418.750.600.650.760 N03.540.348.500.500.600.650.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "United States Food and Drug Administration".
Below are MeSH descriptors whose meaning is more specific than "United States Food and Drug Administration".
This graph shows the total number of publications written about "United States Food and Drug Administration" by people in this website by year, and whether "United States Food and Drug Administration" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 5 | 5 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 4 | 4 |
| 2009 | 1 | 5 | 6 |
| 2010 | 0 | 6 | 6 |
| 2011 | 1 | 11 | 12 |
| 2012 | 1 | 5 | 6 |
| 2013 | 2 | 4 | 6 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 3 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 2 | 10 | 12 |
| 2019 | 2 | 5 | 7 |
| 2020 | 0 | 6 | 6 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 6 | 7 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "United States Food and Drug Administration" by people in Profiles.
-
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority. Clin Transl Sci. 2025 Sep; 18(9):e70337.
-
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review. J Crohns Colitis. 2025 Jul 03; 19(7).
-
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs. Clin Pharmacol Ther. 2025 Oct; 118(4):772-777.
-
Artificial Intelligence in Dermatology: A Comprehensive Review of Approved Applications, Clinical Implementation, and Future Directions. Int J Dermatol. 2025 Sep; 64(9):1568-1583.
-
Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US Food and Drug Administration. Oncologist. 2025 Mar 10; 30(3).
-
Cross-sectional evaluation of medical reversals among National Institute of Health guideline practices implemented during the COVID-19 pandemic: how often did experts err in a time of crisis? BMJ Open. 2024 Dec 20; 14(12):e085210.
-
Discussion of Heated Tobacco Products on Twitter Following IQOS's Modified-Risk Tobacco Product Authorization and US Import Ban: Content Analysis. J Med Internet Res. 2024 10 24; 26:e53938.
-
Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access. J Natl Compr Canc Netw. 2024 08; 22(6):435-436.
-
Mitigation of errors on an FDA-approved platform for cytomegalovirus viral load assay. J Clin Microbiol. 2024 Jul 16; 62(7):e0041624.
-
How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting Decisions. Ther Innov Regul Sci. 2024 07; 58(4):579-590.